Most Popular News Stories on OBR Daily
The ten most read articles from OBR daily in the past two weeks, updated continually:
.gif)
#1: 21 Drugs Facing FDA Approval Decisions
(TheStreet) August 31, 2010 - The fall will be a very busy time for U.S. drug approvals...Avastin for metastatic breast cancer...Prolia for bone complications in cancer patients...Ipilimumab for melanoma...
read article »
#2: The Cancer Trial Bristol and Roche Must Do Now
(Forbes Treatments Blog) August 26, 2010 - Novartis’ Gleevec is an exception. Curing cancer won’t happen with a single drug. Common cancers are too complicated and have too many mutations. The solution, many cancer researchers hope, are smart drug combos that hit multiple tumor weak points at once.
read article »
#3: ASCO Urges CMS to Withdraw National Coverage Analysis for FDA-Approved Cancer Drug
(ASCO in Action) August 23, 2010 - Recently, ASCO submitted comprehensive comments to the Centers for Medicare & Medicaid Services (CMS) expressing concern regarding its decision to open a national coverage analysis (NCA) for an FDA-approved cancer treatment.
read article »
#4: Roche's Hopes For Speedy Drug Approval Dashed
(DowJones/NASDAQ) August 27, 2010 - Roche Holding AG's hopes for a speedy approval of a new breast cancer drug were dashed Friday after U.S. regulators rejected a priority review of T-DM1, adding another item to the growing list of drug development delays and setbacks at the Swiss pharma giant.
read article »
#5: Michael Douglas: 31 Days in the Life of a Throat Cancer Patient
(ABC News) September 3, 2010 - Another throat cancer patient tells of working his way through treatment, side-effects.
read article »
#6: Penn Study Makes Breakthrough in Shrinking Tumors of Terminal Melanoma Patients
(Philadelphia Inquirer) August 26, 2010 - In a major advance against the deadliest type of skin cancer, a genetically targeted drug shrank tumors throughout the bodies of 80 percent of patients with terminal melanoma.
read article »
#7: Two Clinical Trials Target ‘Triple Negative’ Breast Cancer
(OSUCCC-James) August 31, 2010 - Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute are recruiting patients for two clinical trials for women with “triple negative” breast cancer, an aggressive form of breast cancer that resists treatment.
read press release »
#8: Promising New Melanoma Drug: Questions and Answers
(USA Today) August 26, 2010 - A new drug for the treatment of advanced melanoma is generating rare excitement and optimism among cancer doctors. USA TODAY asked experts to explain the drug's benefits and limitations.
read article »
#9: Pfizer's Sutent Fails to Improval Survival Time in Lung Cancer Research
(Bloomberg) August 23, 2010 - Pfizer Inc.’s cancer treatment Sutent failed in a large-scale study to improve overall survival in patients with a form of lung cancer.
read article »
#10: Opinion: Our View on Drug Approvals: Let Science Guide Policy on Costly Breast Cancer Treatments
(USA Today) August 24, 2010 - Let's assume for the moment that you, dear reader, have the power to decide which miracle drugs should be put on the market and which should be kept off because they don't work.
read article »